Login to Your Account


Female sexual disorder reload in Palatin's phase III victory

By Randy Osborne
Staff Writer

Thursday, November 3, 2016

The world had to wait for them about a month longer than expected, but Palatin Technologies Inc.'s positive phase III data with bremelanotide in premenopausal women diagnosed with hypoactive sexual desire disorder (HSDD) should turn up the heat on already busy partnering talks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription